Association between urinary albumin excretion and serum dehydroepiandrosterone sulfate concentration in male patients with type 2 diabetes: A possible link between urinary albumin excretion and cardiovascular disease

Diabetes Care

Volumn 27, Issue 12, 2004, Pages 2893-2897

  Fukui, Michiaki ^a   Kitagawa, Yoshihiro ^b   Nakamura, Naoto ^a   Kadono, Mayuko ^a,b   Hasegawa, Goji ^a   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b WEST JAPAN RAILWAY COMPANY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; PRASTERONE SULFATE;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; HORMONE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

AGE OF ONSET; ALBUMINURIA; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DEHYDROEPIANDROSTERONE SULFATE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 9444266465     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.12.2893     Document Type: Article

References (30)

1. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
2. Multiple Risk Factor Intervention Trial Research Group: Multiple Risk Factor Intervention Trial: risk factor changes in mortality results. JAMA 248:1465-1470, 1982
3. Castelli WP: Lipids, risk factors and ischemic heart disease. Atherosclerosis 124: S1-S9, 1996
4. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998
5. Dinneen SF, Gerstein HC: The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 157:1413-1418, 1997
6. Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endotherial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes 51:1157-1165, 2002
7. Haffner SM, Valdez RA, Mykkanen L, Stern MP, Katz MS: Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 43: 599-603, 1994
8. Kawano H, Yasue H, Kitagawa A, Hirai N, Yoshida T, Soejima H, Miyamoto S, Nakano M, Ogawa H: Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 88: 3190-3195, 2003
9. Byrne JJ, Bradlow HL: DHEA-PC slows the progression of type 2 diabetes (non-insulin-dependent diabetes mellitus) in the ZDF/Gmi-fa/fa rat. Diabetes Technol Ther 3:211-219, 2001
10. Ishizuka T, Kajita K, Miura A, Ishizawa M, Kanoh Y, Itaya S, Kimura M, Muto N, Muse T, Morita H, Yasuda K: DHEA improves glucose uptake via activations of protein kinase C and phosphatidylinositol 3-kinase. Am J Physiol 276:E196-E204, 1999
11. Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB: Low dehyroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol 153: 79-89, 2001
12. Hak AE, Witteman JC, deJong FH, Geerlings MI, Hofman A, Pols HA: Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87:3632-3639, 2002
13. Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr, Pearson TA: Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 16:862-870, 1990
14. LaCroix AZ, Yano K, Reed DM: Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 86:1529-1535, 1992
15. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML: Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87:261-269, 1993
16. Gordon GB, Bush DE, Weisman HF: Reduction of atherosclerosis by administration of dehydroepiandrosterone: a study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest 82:712-720, 1988
17. Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich J, Falk W, Lang B: Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 83:2012-2017, 1998
18. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 25 (Suppl. 1):S5-S20, 2002
19. Mykkanen L, Zaccaro DJ, O'Leary DH, Howard G, Robbins DC, Haffner SM: Microalbuminuria and carotid artery intimamedia thickness in nondiabetic and NIDDM subjects: the Insulin Resistance Atherosclerosis Study (IRAS). Stroke 28: 1710-1716, 1997
20. Kuusisto J, Mykkanen L, Laakso M: Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 91:831-837, 1995
21. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Voutilainen E, Penttila I, Pyorala K: Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33: 237-243, 1990
22. Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC: Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbumiuria. Br Med J 298:487-490, 1989
23. Mattock MB, Barnes DJ, Viberti GC, Keen H, Burt D, Hughes JM, Fitzgerald AP, Sandhu B, Jackson G: Microalbuminuria and coronary heart disease in NIDDM: an incident study. Diabetes 47:1786-1792, 1998
24. Richards RJ, Porter JR, Inserra F, Ferder LF, Stella I, Reisin E, Svec F: Effects of dehydroepiandrosterone and quinapril on nephropathy in obese Zucker rats. Kidney Int 59:37-43, 2001
25. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macia M, Mendez ML, Garcia J: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33:458-463, 1999
26. Kimura M, Tanaka S, Yamada Y, Kiuchi Y, Yamakawa T, Sekihara H: Dehydroepiandrosterone decreases serum tumor necrosis factor-alpha and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese Zucker fatty rats. Endocrinology 139:3249-3253, 1998
27. Okamoto K: Relationship between dehydroepiandrosterone sulfate and serum lipid levels in Japanese men. J Epidemiol 6:63-67, 1996
28. Jesse RL, Loesser K, Eich DM, Qian YZ, Hess ML, Nestler JE: Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann N Y Acad Sci 774:281-290, 1995
29. Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT: The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int 21:730-738, 1982
30. Wiseman MJ, Viberti GC, Mackintosh D, Jarrett RJ, Keen H: Glycaemia, arterial pressure and microalbuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 26:401-405, 1984